Amal Alrashidi

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Metabolic Syndrome

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Jawaher Abdullah Alamoudi, Thanaa A El-Masry, Mohamed Nasr, Ismail T Ibrahim, Hanaa A Ibrahim, Hebatallah M Saad, Maysa M F El-Nagar, Samar Zuhair Alshawwa, Amal Alrashidi, Enas I El Zahaby
Fabrication of Nanocrystals for Enhanced Distribution of a Fatty Acid Synthase Inhibitor (Orlistat) as a Promising Method to Relieve Solid Ehrlich Carcinoma-Induced Hepatic Damage in Mice. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Jawaher Abdullah Alamoudi, Thanaa A El-Masry, Mohamed Nasr, Ismail T Ibrahim, Hanaa A Ibrahim, Hebatallah M Saad, Maysa M F El-Nagar, Samar Zuhair Alshawwa, Amal Alrashidi, Enas I El Zahaby
Fabrication of Nanocrystals for Enhanced Distribution of a Fatty Acid Synthase Inhibitor (Orlistat) as a Promising Method to Relieve Solid Ehrlich Carcinoma-Induced Hepatic Damage in Mice. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Jawaher Abdullah Alamoudi, Thanaa A El-Masry, Mohamed Nasr, Ismail T Ibrahim, Hanaa A Ibrahim, Hebatallah M Saad, Maysa M F El-Nagar, Samar Zuhair Alshawwa, Amal Alrashidi, Enas I El Zahaby
Fabrication of Nanocrystals for Enhanced Distribution of a Fatty Acid Synthase Inhibitor (Orlistat) as a Promising Method to Relieve Solid Ehrlich Carcinoma-Induced Hepatic Damage in Mice. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)